
Alpenglow Biosciences: Accelerating drug development with AI-enabled 3D imaging technology since 2018.
Founded in 2018, Seattle-based Alpenglow Biosciences is a privately held life sciences company dedicated to accelerating drug development and enhancing clinical diagnostics through AI-enabled 3D imaging technology. Their innovative platform offers new spatial biology insights, providing greater accuracy and depth in biological research and medical diagnostics. Alpenglow Biosciences primarily focuses on the pharmaceutical and healthcare markets, aiming to revolutionize how diseases are understood and treated.
Notable figures affiliated with Alpenglow Biosciences include experts in AI, imaging, and life sciences, although specific names are not provided. The company has attracted attention from key investors in the biotech industry, contributing to its rapid growth and development. Alpenglow Biosciences' achievements include pioneering advancements in 3D spatial biology that have significant implications for drug development and clinical diagnostics, positioning the company as a leader in the integration of AI and imaging technologies in life sciences.

Alamar Biosciences
alamarbio.com

Alzeca Biosciences
alzeca.com

Algen Biotechnologies
algenbio.com

Elucid Bioimaging

Regenerative Bio
regen-bio.us

Amplified Sciences

Magnify Biosciences
magnifybiosci.com

Avelas Biosciences

Longevity InTime BioTech
intime.digital

OneThree Biotech
onethree.bio

Alveo Technologies

Enable Medicine
enablemedicine.com

Curi Bio
curibio.com

Lumen Bioscience

BioAI Health
bioaihealth.com
Companies similar to Alpenglow Biosciences include Alamar Biosciences, Alzeca Biosciences, Algen Biotechnologies and Elucid Bioimaging.
Alpenglow Biosciences was founded in 2018.
Alpenglow Biosciences' headquarters is located in Seattle, WA, US.
Alpenglow Biosciences' most recent funding round was for $1.6M (USD) in August 2023.
As of Aug 1, 2023, Alpenglow Biosciences has raised a total of $5.6M (USD).
Alpenglow Biosciences has 22 employees as of Feb 4, 2024.